CD19-targeted chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19-CAR T-cell products received FDA and EMA approval designations in lymphoma in the third-line setting, paving the way for follow-up studies in the second-line. Meanwhile, investigations into the applications of CAR T-cell therapy have further broadened to treating high-risk patients even prior to completion of first-line conventional chemo-immunotherapy. Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19-CAR T-cells in primary and secondary CNS lymphoma. Here we provide a detailed overview on clinical data supporting the use of CAR T-cells in patients with LBCL.
Keywords: B-cell lymphoma; CD19; autologous stem cell transplantation (ASCT); chimeric antigen receptor (CAR) T cell; diffuse large B-cell lymphoma (DLBCL); non-Hodgkin lymphoma (NHL); primary CNS lymphoma (PCNSL); secondary CNS lymphoma (SCNSL).
© 2023 John Wiley & Sons Ltd.